Campbell & Co Investment Adviser’s Axsome Therapeutics AXSM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,770	Closed	-$637K	–	1046
2026 Q1	$637K	Sell	3,770 -8,689	-70%	-$1.5M	0.04%	666
2025 Q4	$2.28M	Buy	12,459 +6,382	+105%	+$891K	0.11%	287
2025 Q3	$738K	Sell	6,077 -3,177	-34%	-$358K	0.06%	553
2025 Q2	$966K	Buy	+9,254	New	+$980K	0.06%	514
2024 Q2	–	Sell	-4,869	Closed	-$389K	–	1053
2024 Q1	$389K	Buy	+4,869	New	+$409K	0.03%	812

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Campbell & Co Investment Adviser's AXSM Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 3,770 shares — an estimated $637K sold.

Campbell & Co Investment Adviser first reported a position in AXSM in Q1 2024 and held it in 5 quarters. The position peaked at $2.28M in Q4 2025. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 3,770 Axsome Therapeutics shares in Q2 2026, an estimated $637K.
Campbell & Co Investment Adviser first reported a position in Axsome Therapeutics in Q1 2024 and held it in 5 quarters.
Campbell & Co Investment Adviser's Axsome Therapeutics position peaked at $2.28M in Q4 2025.
190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.